Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, Piaggi S, Materazzi G, Spinelli C, Fontanini G, Danesi R, Da Settimo F, Miccoli P.

J Clin Endocrinol Metab. 2014 Apr;99(4):E572-81. doi: 10.1210/jc.2013-2321. Epub 2014 Jan 1.

PMID:
24423321
2.

CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Di Desidero T, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P.

J Clin Endocrinol Metab. 2012 Apr;97(4):E528-36. doi: 10.1210/jc.2011-1987. Epub 2012 Jan 25.

PMID:
22278419
3.

Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.

Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P.

J Clin Endocrinol Metab. 2011 Feb;96(2):E288-96. doi: 10.1210/jc.2010-1905. Epub 2010 Dec 8.

PMID:
21147882
4.

Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.

Ferrari SM, Fallahi P, La Motta C, Bocci G, Corrado A, Materazzi G, Galleri D, Piaggi S, Danesi R, Da Settimo F, Miccoli P, Antonelli A.

Surgery. 2014 Nov;156(5):1167-76. doi: 10.1016/j.surg.2014.05.005. Epub 2014 Aug 21.

PMID:
25151558
5.

Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.

Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1465-73. doi: 10.1210/jc.2013-1364. Epub 2013 Aug 22.

PMID:
23969186
6.

CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.

Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Corrado A, Fioravanti A, Sartini S, Orlandi P, Piaggi S, Corti A, Materazzi G, Galleri D, Ulisse S, Fontanini G, Danesi R, Da Settimo F, Miccoli P.

Mol Cell Endocrinol. 2014 Aug 5;393(1-2):56-64. doi: 10.1016/j.mce.2014.06.002. Epub 2014 Jun 12.

PMID:
24931161
7.

Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.

Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, Jimeno J, Francis GL.

Cancer Chemother Pharmacol. 2006 Jan;57(1):7-14. Epub 2005 Nov 5.

PMID:
16001179
8.

PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.

Che HY, Guo HY, Si XW, You QY, Lou WY.

Tumour Biol. 2014 Sep;35(9):8659-64. doi: 10.1007/s13277-014-2118-3. Epub 2014 May 28.

PMID:
24867098
9.

CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.

Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A.

Endocrine. 2016 Jul;53(1):136-44. doi: 10.1007/s12020-015-0717-4. Epub 2015 Aug 19.

PMID:
26286966
10.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

12.

Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.

Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.

Clin Cancer Res. 2006 Aug 1;12(15):4755-65.

13.

Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.

Wunderlich A, Khoruzhyk M, Roth S, Ramaswamy A, Greene BH, Doll D, Bartsch DK, Hoffmann S.

J Surg Res. 2013 Dec;185(2):676-83. doi: 10.1016/j.jss.2013.06.017. Epub 2013 Jun 29.

PMID:
23845866
14.

The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.

Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA, Myers JN.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4519-27.

15.

New targeted therapies for anaplastic thyroid cancer.

Antonelli A, Fallahi P, Ulisse S, Ferrari SM, Minuto M, Saraceno G, Santini F, Mazzi V, D'Armiento M, Miccoli P.

Anticancer Agents Med Chem. 2012 Jan;12(1):87-93.

PMID:
22043992
16.

Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN.

Mol Cancer Ther. 2007 Jun;6(6):1785-92.

17.

Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.

Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY.

Clin Cancer Res. 2011 Apr 15;17(8):2281-91. doi: 10.1158/1078-0432.CCR-10-2762. Epub 2011 Jan 10.

18.

YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.

Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.

Clin Cancer Res. 2006 Mar 1;12(5):1630-8.

19.

Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.

Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C.

Endocrinology. 2004 Mar;145(3):1031-8. Epub 2003 Nov 7.

PMID:
14607854
20.

Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.

Donnini S, Monti M, Castagnini C, Solito R, Botta M, Schenone S, Giachetti A, Ziche M.

Int J Cancer. 2007 Mar 1;120(5):995-1004.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk